JZT(SZ:000989) Zheng Quan Ri Bao Wang·2025-10-29 13:13Core Insights - JiuZhiTang has acquired a 51.6667% stake in Harbin JiXiangLong Biotechnology Co., Ltd. for RMB 2.1 billion and invested an additional RMB 1 billion, allowing JiXiangLong to be included in JiuZhiTang's consolidated financial statements [1][2] - JiXiangLong specializes in the research, production, and technical services of peptide-based generic drugs and innovative drugs, holding 10 production approvals for raw materials and 1 for formulations, with 8 products entering national procurement [1][2] - The acquisition enables JiuZhiTang to enter the peptide raw material drug sector, enhancing its product range and industrial chain layout [1][2] Company Overview - JiXiangLong is recognized as a national high-tech enterprise with a strong technical team and a comprehensive technology system in the peptide drug field, indicating significant growth potential and investment value [2] - JiuZhiTang is a pharmaceutical company that integrates research, production, sales, and health management, focusing on traditional and modern Chinese medicine, biopharmaceuticals, and health products [2] - The integration is expected to create synergies in production, sales channels, research, and technology, enhancing JiuZhiTang's competitiveness in the pharmaceutical sector [2] Market Implications - The deep integration of JiuZhiTang and JiXiangLong is anticipated to improve the company's risk resilience, profitability, and growth potential, with ongoing market attention on the integration effects and synergy value [2]